Hepatitis B and C infections, and co-infections screening among patients attending a tertiary hospital in Addis Ababa, Ethiopia: a retrospective database study Authors: Balew Arega, Ermiyas Tefera, Kibrom Mesfin, Daniel Achame, Dawit Tolossa, Abenezer Worku, Ermias Kibru, Nebyu Tafasse, Amdemeskel Mersha Published: 2025 ABSTRACT AbstractBackgroundHepatitis B and C virus infection is a continuous public health problem in Ethiopia, with the prevalence of the disease significantly varying across administrative regions. Determining seroprevalence among people who are unaware of their infection status is essential for hepatitis diagnosis and treatment. We aimed to determine the seroprevalence of two hepatitis viruses among patients attending different service areas in a tertiary hospital in Ethiopia.MethodsWe conducted an institution-based retrospective study using serology laboratory data from January 2021 to December 2023 at Yekatit 12 Hospital Medical College in Addis Ababa. We retrieved hepatitis B virus and hepatitis C virus data from electronic databases. We ran a binary logistic regression analysis to assess the relationship between dependent and independent variables. Statistical significance was determined for variables having a P-value (P < 0.05) and 95% confidence intervals.ResultsA total of 3332 and 9890 patients’ blood samples were screened for hepatitis B and C virus, respectively. The prevalence of hepatitis B was 5.4% (179/3332), and hepatitis C virus was 1.8% (175/9890). The overall prevalence of co-infection was 0.2% (7/3322). Hepatitis B virus prevalence fluctuated, while hepatitis C virus prevalence steadily increased from 2021 to 2023. The positivity rate of the hepatitis B virus is 5.4% (89/1643) and hepatitis C virus 1.86% (93/5414) among female patients. Age was significantly associated with hepatitis B and C virus infection. The two viruses have been found at a significantly higher prevalence rate among admitted and emergency department patients.ConclusionAn intermediate seroprevalence of HBV and hepatitis C virus infection was detected among participants in our study area. Screening for hepatitis B and C can be beneficial in identifying people with viral hepatitis and offering a chance to engage them in specialized care.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12876-025-04541-3.Keywords: Addis ababa, HBV, HCV, Patients Background Hepatitis B (HBV) and hepatitis C viruses (HCV) constitute a major threat to the public’s health, infecting millions of individuals every year [1]. These viruses infect around 320 million individuals globally, more than HIV, tuberculosis, and malaria combined [1]. An estimated 1.3 million people died from chronic viral hepatitis B and C in 2022 (3500 deaths per day) [2]. The greater burden of mortality is documented in Sub-Saharan Africa and East Asia, where most of the patients were undiagnosed, had delayed diagnosis, and with no alternative treatment options [3]. Eliminating HBV and HCV will result in significant public health and economic advantages [4]. In 2016, member nations of the World Health Assembly overwhelmingly endorsed a resolution proclaiming viral hepatitis to be eliminated by 2030 [5]. However, according to the interim study, about 89.7% of HBV and 78.6% of HCV infections go undetected, and just 12 nations are on track to meet hepatitis elimination goals [6]. This suggests that more substantial efforts should be made promptly to increase viral hepatitis screening and treatment. Ethiopia has an intermediate to hyperendemic level of hepatitis endemicity [7], with the disease’s incidence significantly varying among administrative regions as well as study settings [8]. In the country, persistent HBV and HCV infections are responsible for more than 60% of chronic liver disease and almost 80% of hepatic cell carcinoma [9]. In recent meta-analyses, the pooled prevalence of HBV was 6% [8] and HCV was 2% [10]. The majority of studies in this meta-analysis were conducted among blood donors, community surveillance, and a limited number of hospital patients. The community-based seroprevalence of the HBV virus in Addis Ababa was 7%, yet there was no data available on the seroprevalence of the HCV virus in the same population [11]. HBsAg was reported among various segments of society, such as among pregnant women (3.04–4.5%) [12, 13], human immunodeficiency patients (HIV) (3.6–5.96%) [14, 15], voluntarily tested for HIV individuals (5.7%) [16], and chronic Liver Diseases (35.5%) [17]. Similarly, the magnitude of HCV among different populations, such as HIV (1.72%) [15], chronic Liver Diseases (22.5%) [17], and hemodialysis (2.8%) [18] was determined in Addis Ababa. The N studies were carried out on a particular group that either had clinical symptoms or was at high risk of HBV or HCV infection. However, there are no studies that assessed HBV and HCV in the asymptomatic hospital-visiting patients in Addis Ababa. Increasing the efficacy of interventions should start with testing, which is required to identify the many people who are unaware of their viral hepatitis diseases. Testing for HBV and HCV whenever possible, commencing treatment, and achieving viral suppression or cure comprise a continuum of care that may be used to assess and improve efforts to address these endemic health challenges in Ethiopia. Healthcare workers have an essential role in disease detection and prevention since they are the first point of contact for undiagnosed patients and have a comprehensive understanding of risk factors. As a result, the purpose of this study was to assess the prevalence of HBV and HCV infection among patients who visited outpatient clinics, emergency departments, and hospitals over three years. Methods Study area, design, and period We conducted a retrospective analysis of all patients screened for HBV and HCV from January 2021 to December 30, 2023, at Yekatit 12 Hospital Medical College, a teaching hospital in Addis Ababa, Ethiopia. The hospital is among the largest in the country, having over 500 beds, serving over 310,000 people annually, and comprises over 21 departments. The hospital began deploying an electronic medical record (EMR) system in late 2019, which is being implemented for recording patient data. The hospital offered several laboratory services for emergency, outpatient, and inpatient care. Laboratory tests request and results were done using the EMR. Study population, variables, and sample size We included the HBV and HCV screening results of emergency, outpatient, and admitted patients from January 2021 to December 30, 2023. We retrieved data from the laboratory EMR system database between February 1 and 30, 2024. We utilize the checklist to extract data from the laboratory EMR about gender, age, HBV and/or HCV status, the department requesting the information, and the year of the request. We excluded patients’ data with the following criteria. (1) if the serologic test was requested for symptomatic patients or the diagnosis was hepatitis of any stage, and (2) we also excluded patients with missing data, such as sex, age, HBV and HCV test outcome, and other important variables. Laboratory methods The presence of HBsAg and anti-HCV antibodies in serum/plasma was determined using a one-step Cassette Style HBsAg test kit. The HBsAg test strip (ACON Laboratories, Incorporated, San Diego, California, USA) has 100% sensitivity and specificity, while the anti-HCV antibody test strip (Wondfo Biotech Co., Ltd., Guangzhou, PRC) has 99% sensitivity and 99.8% specificity. We did not further investigate to confirm potential false positive anti-HCV test results, occult infection in HBV-infected patients, or polymerase chain reaction (PCR) for anti-HCV test and HBsAg-positive patients. Data processing and analysis We used the Statistical Package for Social Sciences (SPSS) version 27 database for entry, cleaning, and analysis. Bivariate and multivariable logistic regression analyses were used to identify HBV and HCV risk factors. Variables having a p-value of less than 0.2 in bivariate analysis were used to construct the final multivariable logistic regression model using a stepwise approach. For determining the strength of the association and degree of significance, an odds ratio with a 95% confidence interval and a p-value less than 0.05 was used. Results Sociodemographic characteristics and magnitude of HBV infection During the study period, a total of 3332 patients were screened for HBV infection using the HBsAg test. The mean age of patients was 39 ± 18.77 years, with males accounting for 50.7% (1643/3332). The majority, 58.76% (1958/3332), of the sample screened for HBV infection was from outpatient clinics (Table 1). The magnitude of HBV infection was 5.4% (179/3332). The magnitude of the three-year trend of HBV infection was 5.1% in 2021, decreased to 4.8% in 2022, and reached 5.6% in 2023(Fig. 1). The magnitude of HBV infection among female patients was 5.4% (89/1643), among patients aged 31 to 45 years was 7.8% (95/958), 7.3% (65/894), and 7.44% (33/443) among patients screened in the inpatient department (Table 1). Table 1Sociodemographic characteristics and magnitude of HBV and HCV infectionVariablesTotal patients screened for HBV(n=3332)HBV Positive(n,%)Total patients screened for HCV(n=9890)Positive(n,%)Sex Male168990(5.3)541493(1.8) Female164389(5.4)447683(1.86)Age groups <152281(0.44)8176(0.7) 16–3089465(7.3)296430(1.01) 31–4595875(7.8)294838(1.28) >45125238(3.03)3161101(3.2)Examination room Inpatient44333(7.44)123330(2.43) Emergency93152(5.55)247353(2.14) Outpatient195894(4.80)618492(1.48) Sociodemographic characteristics and magnitude of HBV and HCV infection The trend of HBV and HCV infection from January 2021 to December 2023 Sociodemographic characteristics and magnitude of HCV infection A total of 9890 patients were screened using an anti-HCV antibody test for HCV infection during the study period. The mean age was 36 ± 18.0 years, and more than half, 54.7% (5414/9890), were males. More than two-thirds, 62.5% (6184/9890) of HCV requests were from outpatient clinics (Table 1). The magnitude of HBV was 1.8% (175/9890). The magnitude of HCV infection trended upward from 1.4% in 2021 to 1.8% in 2022 and 2.1 in 2023 (Fig. 1). The positivity rate of HBV infection was 1.86% (93/5414) among females, 3.2% (101/3161) among patients aged above 45 years, and 2.43% (30/1233) among hospitalized patients (Table 1). Magnitude of HBV and HCV co-infection A total of 3322 patients were screened for both HBV and HCV. The magnitude of co-infection was 0.2%(7/3322). Almost all patients tested for HBV; 99.7% (3322/3332) were also tested for HCV infection. However, more than two-thirds (66.7%) of the individuals tested for HCV had no recorded or requested HBV infection screening. Factors associated with hepatitis HBV and HCV infection The three variables that were examined in the univariate logistic analysis—age, sex, and department—all had p-values less than 0.2 and were incorporated into the multivariate logistic regression. In multivariate logistic analysis, patients aged 15–30 years (AOR, 7.8, 95% CI 2.32,13.87), 31–45 years (AOR, 8.11, 95% CI 2.50,17.11), and above 45 years (AOR, 6.74, 95% CI 1.92,19.41) had significantly higher HBV infection rates than those aged less than 15 years. HBV infection was significantly higher among inpatients (AOR,2.33, 95% CI 1.63,3.77) and emergency department patients (AOR,1.63, 95% CI 1.21, 2.78) than in patients in outpatient clinics (Table 2). HCV was also significantly higher among patients aged above 45 years (AOR,4.46, 95%CI 1.95,10.2), among emergency (AOR,1.55, 95%1.03,2.04), and inpatients (AOR, 1.65, 95%CI 1.09,2.50) departments patients compared to their counterparts (Table 2). Table 2Factors associated with HBV and HCV infection among study participantsVariablesHBV positiveHCV positiveAOR(95%CI),p-valueAOR(95%CI),p-valueSex Male11 Female1.042(0.77,1.41),0.771.07(0.79,1.4),0.69Age groups <1511 15–307.8(2.32,13.87),0.04*1.38(0.57,3.33), 0.47 31–458.11(2.50,17.11),0.05*1.76(0.74,4.19), 0.19 >456.74(1.92,19.41),0.042*4.46(1.95,10.2),0.001*Examination room Inpatients2.23(1.63,3.77),0.03*1.55(1.03,2.04),0.03* Emergency outpatients1.78(1.21, 2.78),0.012*1.65(1.09,2.50),0.02* Outpatient clinics11*significantly associated(p<0.05). AOR Adjusted Odd ratio, HBV Hepatitis B Virus, HCV Hepatitis C Virus, CI Confidence interval Factors associated with HBV and HCV infection among study participants *significantly associated(p<0.05). AOR Adjusted Odd ratio, HBV Hepatitis B Virus, HCV Hepatitis C Virus, CI Confidence interval Discussion In this study, we looked at the prevalence of HBV, HCV, and co-infection, as well as their distribution by gender, age, and service areas. We found that the prevalence of HBV was 5.4%, HCV was 1.8%, and confection was 0.2%. The prevalence of HBV was roughly comparable throughout the three years; however, HCV increased from 1.4 to 2.1% between 2021 and 2023. Both infections were significantly higher among individuals over the age of 15 years and among those in emergency and admitted patients. The prevalence of HBV infection was reported to be (hyperendemic) >8% among the general population in Saharan countries such as Nigeria, Namibia, Gabon, Cameroon, and Burkina Faso. In this study [19]. The seroprevalence of HBV infection (5.4%) in our study was lower compared to previous studies done in other regions of Ethiopia, 9% in Hawassa [9], 14.6% in Gondar [10], and other African nations, 6.94% in Ghana [11], and 13.60% in Nigeria [12]. However, our findings are greater than those obtained in northern Ethiopia, Adigrat, at 3.57% [13]. The findings revealed that the extent of HBV varied not just among countries, but also throughout our country’s regions. This might be due to host variables, socioeconomic factors, the setting of the study, laboratory test type, or the study participant. In this example, a study done in Gondar included clinically suspected viral hepatitis patients, whereas the patients in our study included not only viral hepatitis suspects but also surgical patients and others. In our study, only one (0.44%) child patient was infected with HBV. In urban Ethiopian children, a community-based study, the prevalence rates of HBV among children in the Gambella, Addis Ababa, and Amhara regions, with values of 2.37%, 2.14 and 2.11%, respectively [20].The prevalence of HBV infection among children is lower in Ethiopia compared to other studies in southern sub-Saharan Africa, 5% [21]. The low prevalence in our study might be the HBV vaccination program, the difference in the testing tools, the population, and the study setting. Our study HCV prevalence (1.8%) was similar to a hospital-based study in India (1.76%) [9] and another study at Adigrat Hospital in northern Ethiopia (2.13%) [10]. In contrast, it is significantly lower than Gondar’s University Hospital in northern Ethiopia (12.4% HCV) [10], Hawassa University Hospital in southern Ethiopia (5.5% HCV) [11], and in Nigeria (16.6% HCV) [22]. On the other hand, our findings were about eight times higher than the study conducted among emergency patients in a large London teaching hospital [23]. The seroprevalence of HCV in hospital-based populations varies widely, possibly due to a combination of behavioral, social, study environment, type of testing, host characteristics impacting transmission, and intervention undertaken in different countries [24]. In addition, some studies have different laboratory methods, including ELISA and PCR, compared to the rapid diagnostic test employed in the present study [23]. In the presence of effective HCV medication, screening high-risk individuals and further testing before therapy starts will prevent disease transmission and progression on an individual level. The co-infection rate of HBV and HCV in this study was 0.21% which is similar to the study done at Hawassa University Hospital in southern Ethiopia (0.2%) [25] and in tertiary care hospital in India (0.16%) [26] but lower than the study in Gondar University in Northern Ethiopia, 2% [27] Adigrat Hospital in Northern Ethiopia (7.4%) [28] and Nigeria (8.3%) [22]. Studies showed that due to the sharing of similar transmission routes, co-infection with HBV and HCV was common. Patients with HBV/HCV co-infection are more likely to experience severe illness and a poor response to therapy; thus, early screening and management will result in a good outcome [29]. In our study, HBV among patients over 15 years and HCV among patients over 45 years were significantly associated with an increased risk of infection. Consistently, a study was undertaken at Adigrat and the University of Gondar Hospital in Ethiopia, reporting similar findings [27, 28] and in Nigeria [22]. This might be related to sexual activity in this age range, occupational exposure, and tattooing. This indicates the need to promote awareness among this group about the availability of vaccinations, boost coverage of youth-friendly services in health facilities, take steps to reduce viral transmission, and develop screening guidelines for this age range. In our study, both HBV and HCV were higher among patients screened from the emergency department and hospitalized patients. The magnitude of the infection in this setting was at least 1.5 times higher compared to patients from outpatients. Similarly, previous studies have shown that HCV and HBV were greater among emergency [7, 30] and hospitalized patients [31]. Even though we could not identify the reason for screening these viral markers, patients in the emergency department might have symptoms and have multiple risk factors for viral infection. Emergency departments and inpatients may serve as the primary healthcare gateway for vulnerable groups, who have a higher prevalence of viral hepatitis. Our study had limitations. Because we employed secondary data from the administrative electronic database, we were unable to determine the indication for screening and provide detailed information for identifying potential risk factors. Since we performed a one-step HCV test in our hospital, which has a higher false positive rate in asymptomatic patients, we cannot be confident whether the positive HCV result is an infection. Patients who screened for HBV using HBsAg might have occult infection, and we did not determine it. In addition, we could not include the PCR for viral load determination. Conclusions The prevalence of HBV and HCV among patients in various service areas of a tertiary hospital in Ethiopia was 5.4% and 1.8%, respectively. HBV infection remained stable over three years, whereas HCV infection increased. Adult age groups, as well as patients from emergency rooms and admitted patients, were significantly associated with higher HBV and HCV infection rates. An intermediate seroprevalence of HBV and HCV infection was detected among participants in our study area. Therefore, implementing strategies for routine screening of high-risk patients, in our case, adult age groups, hospitalized, and emergency patients for HBV and HCV, can serve as a pathway to identifying patients with previously undetected viral hepatitis infection and enrolling them in specialized care. Supplementary Information Supplementary Material 1. Acknowledgements No special acknowledgment. Abbreviations Electronic medical record Hepatitis C virus Hepatitis B virus Polymerase chain reaction Statistical Package for Social Sciences Authors’ contributions BA and ET designed the study, collected, analyzed, and interpreted data, and drafted the manuscript. KM, DA, DT, AW, EK, NT, and AM designed the study, supervised data extraction, and prepared the manuscript. All authors read and approved the final manuscript. Funding None. Data availability All data analyzed during this study are included in this manuscript. Declarations Ethics approval and consent to participate This study strictly adhered to the ethical standards outlined in the Declaration of Helsinki. The institutional review board waived the need for written informed consent from participants due to the retrospective nature of the study and for collecting only secondary data. To keep the privacy of the patients, we omitted the names of patients during data collection and excluded the chart number from publication. Ethical approval was obtained from Yekatit 12 Hospital Medical College, the Institutional Review Board (IRB) - ethics committee number Y12HMC(RPO/542/24). Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Balew Arega and Ermiyas Tefera contributed equally. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement All data analyzed during this study are included in this manuscript.